Primary care diagnosis of alpha-1 antitrypsin deficiency: Issues and opportunities

James K. Stoller, MD, MS
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Vice Chairman, Division of Medicine, Cleveland Clinic; Head, Section of Respiratory Therapy, Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic

Leonard Fromer, MD
Assistant Clinical Professor, Family Medicine, David Geffen School of Medicine, The University of California at Los Angeles

Mark Brantly, MD
Professor of Medicine, Molecular Genetics and Microbiology, Division of Pulmonary and Critical Care Medicine and Department of Biometry, University of Florida College of Medicine; Director, University of Florida Alpha-1 Antitrypsin Genetics Laboratory, University of Florida College of Medicine, Gainesville

James Stocks, MD
Professor of Medicine, Director of the Pulmonary Function and Sleep Laboratories, University of Texas at Tyler

Charlie Strange, MD
Professor, Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston

Address: James K. Stoller, MD, MS, Department of Pulmonary, Allergy, and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail stollej@ccf.org

Dr. Stoller has indicated that he has been a consultant for Talecris and Baxter corporations.

Dr. Brantly has indicated that he has received honoraria from Talecris. Dr. Strange has indicated
that he has been a consultant for Talecris, GTC Biotherapeutics, and Arriva.

James K. Stoller, MD, MS
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Vice Chairman, Division of Medicine, Cleveland Clinic; Head, Section of Respiratory Therapy, Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic

Leonard Fromer, MD
Assistant Clinical Professor, Family Medicine, David Geffen School of Medicine, The University of California at Los Angeles

Mark Brantly, MD
Professor of Medicine, Molecular Genetics and Microbiology, Division of Pulmonary and Critical Care Medicine and Department of Biometry, University of Florida College of Medicine; Director, University of Florida Alpha-1 Antitrypsin Genetics Laboratory, University of Florida College of Medicine, Gainesville

James Stocks, MD
Professor of Medicine, Director of the Pulmonary Function and Sleep Laboratories, University of Texas at Tyler

Charlie Strange, MD
Professor, Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston

Address: James K. Stoller, MD, MS, Department of Pulmonary, Allergy, and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail stollej@ccf.org

Dr. Stoller has indicated that he has been a consultant for Talecris and Baxter corporations.

Dr. Brantly has indicated that he has received honoraria from Talecris. Dr. Strange has indicated
that he has been a consultant for Talecris, GTC Biotherapeutics, and Arriva.

James K. Stoller, MD, MS
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Vice Chairman, Division of Medicine, Cleveland Clinic; Head, Section of Respiratory Therapy, Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic

Leonard Fromer, MD
Assistant Clinical Professor, Family Medicine, David Geffen School of Medicine, The University of California at Los Angeles

Mark Brantly, MD
Professor of Medicine, Molecular Genetics and Microbiology, Division of Pulmonary and Critical Care Medicine and Department of Biometry, University of Florida College of Medicine; Director, University of Florida Alpha-1 Antitrypsin Genetics Laboratory, University of Florida College of Medicine, Gainesville

James Stocks, MD
Professor of Medicine, Director of the Pulmonary Function and Sleep Laboratories, University of Texas at Tyler

Charlie Strange, MD
Professor, Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston

Address: James K. Stoller, MD, MS, Department of Pulmonary, Allergy, and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail stollej@ccf.org

Dr. Stoller has indicated that he has been a consultant for Talecris and Baxter corporations.

Dr. Brantly has indicated that he has received honoraria from Talecris. Dr. Strange has indicated
that he has been a consultant for Talecris, GTC Biotherapeutics, and Arriva.